Anticancer Activity of Rasamanikya in Acute Promyelocytic Leukemia: An In-vitro Cell Line Study Protocol

Introduction: Acute Promyelocytic Leukaemia (APL) is a subtype of Acute Myeloid Leukaemia (AML) characterised by the translocation of chromosomes 15 and 17, leading to the PML-RAR-α fusion gene. Conventional treatments, including chemotherapy and radiation, often have significant side-effects, such as organ damage and secondary cancers. Need of the study: This study will explore the potential anticancer efficacy of Rasamanikya, a traditional Ayurvedic arsenical formulation derived from Shuddha Haratala (arsenic trisulfide), is evaluated in treating APL through in-vitro studies. Rasamanikya, mentioned in ancient Ayurvedic texts as a remedy for blood and skin disorders, is believed to act as an immunomodulator and enhance erythropoiesis. The mineral formulation is rapidly absorbed and acts systemically, potentially reducing adverse effects of conventional therapies while maintaining efficacy. This study aims to evaluate the optimal dose and anticancer potential of Rasamanikya for APL treatment, providing a bridge between traditional medicine and modern oncology. Aim: To evaluate the anticancer activity of Rasamanikya in APL. Materials and Methods: The experimental analytical in-vitro study will be conducted at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Kharghar, Navi Mumbai, and Aakar Biotechnologies Private Limited, Lucknow, Uttar Pradesh, selected for their availability of different cell types, during the period from March 2026 to August 2026 The formulation Rasamanikya, essential for the study, will be sourced from Dattatraya Ayurved Rasashala, Wardha. Its preparation will take place in the Department of Rasa Shastra and Bhaishajya Kalpana at Mahatma Gandhi Ayurved College Hospital and Research Centre, Salod (H), Wardha. The study aims to assess Rasamanikya through in-vitro methods by examining its organoleptic and physicochemical properties in APL. For statistical analysis, the One-way ANOVA test will be applied, with a p-value of less than 0.05 considered to indicate statistical significance.